VITRAKVI Maintains Market Leadership Across the 7MM Amid Growing TRK Inhibitor Competition | DelveInsight
DelveInsight's "VITRAKVI Market Size, Forecast, and Market Insight Report" highlights the details around VITRAKVI, a TRK, ...
DelveInsight Business Research, LLP: ROZLYTREK's Market Growth Reflects Transforming Treatment for NTRK and ROS1-Positive Cancers | DelveInsight
As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...
CURE15d
Gleevec Response in GIST May Be Linked to Mutational Profile
Gleevec response in GIST varies by mutational profile, with KIT-exon-11 mutation linked to better outcomes, emphasizing mutation testing for treatment decisions.
The Daily Telegraph24d
‘Miracle drug’ completely shrinks baby boy’s tumour, after shock cancer diagnosis
NTRK fusion, in solid tumours. “In years past, we would have had to give chemotherapy drugs, big, toxic, strong, nasty chemotherapy drugs that make your hair fall out and give you low blood ...
pharmaphorum2d
Bayer takes control of Loxo duo as Lilly closes takeover
Vitrakvi was approved by the FDA last November for patients with advanced solid tumours with an NTRK gene fusion, and filings in Europe and other markets are in play. Follow-up LOXO-195 – now re ...
pharmaphorum8d
Bayer’s Vitrakvi is first tumour-agnostic drug approved in EU
The EU drugs regulator cleared Vitrakvi (larotrectinib) for the treatment of patients with solid tumours that have an NTRK gene fusion, are locally advanced, metastatic or for whom surgical ...